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Abstract: Age-related macular degeneration (AMD) is considered the most common cause 
of blindness in the over-60 age group in developed countries. There are basically two forms 
of presentation: geographic (dry or atrophic) and wet (neovascular or exudative). Geographic 
atrophy accounts for approximately 85%–90% of ophthalmic frames and leads to a progressive 
degeneration of the retinal pigment epithelium and the photoreceptors. Wet AMD causes the 
highest percentage of central vision loss secondary to disease. This neovascular form involves 
an angiogenic process in which newly formed choroidal vessels invade the macular area. 
Today, intravitreal anti-angiogenic drugs attempt to block the angiogenic events and represent 
a major advance in the treatment of wet AMD. Currently, combination therapy for wet AMD 
includes different forms of radiation delivery. Epimacular brachytherapy (EMBT) seems to be 
a useful approach to be associated with current anti-vascular endothelial growth factor agents, 
presenting an acceptable efficacy and safety profile. However, at the present stage of research, 
the results of the clinical trials carried out to date are insufficient to justify extending routine 
use of EMBT for the treatment of wet AMD. 
Keywords: macular degeneration, radiation, vascular endothelial growth factor, combined 
therapy, intravitreal therapy, vitrectomy
Introduction
Age-related macular degeneration (AMD) is the most common cause of vision impair-
ment among people over 60 years of age. In 2010, the World Health Organization 
estimated that 285 million people were visually impaired. Of these, 246 million had 
low vision, and 39 million were primarily legally blind due to cataract, glaucoma, 
and AMD.1
Epidemiological data on this disease in the European population suggest that 1.7% 
of adults over 55 years may have the condition in its more advanced clinical forms, 
and draw attention to the major social and health problems that this situation may 
create in certain populations with high life expectancy.2 Data from a meta-analysis 
revealed that the prevalence of AMD in the European population aged between 65 and 
75 years ranges between 9% and 25%.3 This prevalence is slightly higher in women 
(1.03%) than in men (0.90%) between the ages of 65 and 69 years and increases with 
age, reaching 2.36% among women aged between 70 and 74 years.3 However, the 
results obtained in different studies of AMD prevalence vary considerably: in one 
meta-analysis of Caucasian populations, 20% of the variability in prevalence rates was 
explained by the marked differences in age, and 50% by study design characteristics.4 
Meanwhile, there is an exponential increase in the AMD prevalence among age groups 
analyzed – as much as 4.2% per decade – with no sex differences, although there is 
some evidence to suggest an increased risk (×1.2) for occurrence in women. Overall, it 
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is estimated that the prevalence of AMD is 1.4% at 70 years 
of age, rising to 5.6% at 80 years and 20% at 90 years.4,5 In 
the US, a population-based study (the Beaver Dam Study) 
of persons aged between 43 and 86 years found a 14.3% 
15-year cumulative incidence of early clinical presentation 
of AMD and a 3.1% incidence of late AMD at baseline.6 In 
the over-75 group, the 15-year cumulative incidence of late 
AMD was 8%.
Population-based meta-analyses have shown prevalence 
of early and late AMD in Caucasian populations aged over 
40 years of around 6.8% and 1.5%, respectively.7 Regarding 
ethnicity, the results of the Baltimore Eye Survey showed 
that the prevalence of advanced AMD clinical forms was 
nine-fold higher in Caucasians than in African–Americans.8 
Recently, the prevalence of the advanced forms of AMD has 
been found to be similar between Asians and Caucasians.9 In 
the Latin American population, various studies have reported 
prevalence ranging from 2.4% to 16.4% in the population 
aged over 50 years with visual acuity less than 20/200.1
From the clinical point of view, AMD has two forms of 
presentation: geographic (dry or atrophic) and wet (neovas-
cular or exudative). The former may represent approximately 
85%–90% of ophthalmic frames of disease and is character-
ized by a slower but progressive degeneration of the retinal 
pigment epithelium (RPE) and the photoreceptors. Wet 
AMD, which accounts for only 10%–15% of clinical forms, 
causes the highest percentage of central vision loss due to 
disease. The neovascular form appears due to an angiogenic 
process in which newly formed choroidal vessels (choroidal 
neovascularization; CNV) invade the macular area.10,11 In 
the geographic form, the pathophysiological mechanism has 
yet to be clarified, but it is thought that it may be a chronic 
inflammation mechanism involving several factors associ-
ated with the activation pathways of complement factors and 
oxidative stress.11,12
Today there is ample scientific evidence to suggest that 
the vascular endothelial growth factor (VEGF) plays a key 
role in the pathophysiology of wet AMD.13–15 These find-
ings have ushered in a new era in the treatment of CNV, 
based on a better understanding of the cellular and molecu-
lar mechanisms associated with disease. Anti-angiogenic 
drugs, used to block the different stages of the VEGF action 
pathways, represent a major advance in the treatment of wet 
AMD. Pegaptanib sodium (Macugen®; Eyetech/Pfizer Inc.) 
was the first drug developed for intravitreal treatment of 
wet AMD. It is a polyethylene glycol aptamer synthesized 
from RNA oligonucleotides which binds selectively with 
high affinity and specificity to the VEGF-A
165
 isoform, 
thus preventing recognition of VEGF by its receptor.16 
Ranibizumab (Lucentis®; Genentech Inc./Novartis Pharma 
AG) is a humanized Fab fragment of a recombinant mono-
clonal antibody (RhuFabV2), which is designed to block all 
isoforms of VEGF-A. Due to its lower molecular weight 
(~48 kDa), following intravitreal administration it easily 
penetrates through the different layers of the retina and 
exerts an inhibitory effect on vascular permeability and 
angiogenesis.17 Bevacizumab (Avastin®; Genentech Inc./
Roche) is a humanized recombinant monoclonal antibody 
(RhuAbV2), which also inhibits all isoforms of VEGF-A 
in a nonselective manner. Although the use of this drug is 
approved for intravenous treatment of some advanced and 
metastatic carcinomas, its repeated intravitreal administration 
in wet AMD cases also demonstrates the ability to reduce 
vascular exudation and block CNV.18 More recently, afliber-
cept (Eylea®; Regeneron Pharmaceuticals Inc./Bayer) – a 
fusion protein with specific high affinity binding to the VEGF 
receptor domains (VEGF-A and VEGF-B) and the placental 
growth factor (PlGF-1 and PlGF-2) – demonstrated its clini-
cal safety and efficacy to suppress CNV in patients with the 
neovascular form of AMD, and its durability of action rela-
tive to other intravitreal anti-VEGF.19 However, at present, 
there are no specific and efficient treatments for the advanced 
form of dry AMD or for its effects on macular area structure 
and function. 
In spite of the significant therapeutic advances made 
in recent years, several areas of concern still remain: for 
instance, the social impact of the disease, its cost in relation 
to the treatment and its benefits, the ability of public health 
care services to organize appropriate clinical monitoring, 
and the need for standardized protocols of action relating to 
therapeutic aspects of the disease, specifically the periodic 
repetition of the intraocular injections. Options for reducing 
the frequency of repeated intravitreal injections are being 
explored, such as combined treatment with photodynamic 
therapy (verteporfin) or radiation therapy (proton therapy, 
stereotactic radiation, and epimacular brachytherapy), 
which seem scientifically plausible due to their synergistic 
effects. However, the problems mentioned have not yet been 
resolved, and are compounded by the irrefutable fact that 
global life expectancy is increasing, especially in popula-
tions in the industrially developed countries and in emerging 
economies. 
Advanced age is the main risk factor for AMD. More 
than 10% of people over age 80 have widespread forms of 
the disease.20,21 Ocular risk factors are a light-colored iris, 
prior cataract surgery, and hyperopia.11,22 One meta-analysis 
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suggested that cataract surgery is a significant added risk for 
the onset of AMD, although this association has not been 
conclusively demonstrated.22 General and systemic risk fac-
tors include smoking, obesity, excessive sun exposure, and 
cardiovascular disease.11 Cigarette consumption is a particu-
larly important risk factor, and in fact is the only preventable 
one.22 Recently, cardiovascular risk factors have also been 
associated with the development of pathology; people with 
AMD also have a higher risk for cardiovascular disease and 
a predisposition to stroke.11,23 So the potential risk factors are 
1) age, 2) smoking, 3) family history and genetic predisposi-
tion (certain genetic polymorphisms are associated with an 
increased risk of the disease), 4) sex (women seem to be 
more prone to develop the disease), 5) ethnicity (the preva-
lence is higher in Caucasian populations), 6) hypertension 
and cardiovascular disease, 7) light-colored iris (blue eyes), 
8) excessive exposure to sunlight (ultraviolet radiation), 
9) poor nutritional states (intake of antioxidant supplements 
[vitamins C, E, and zinc], carotenoids [lutein and zeaxan-
thin], and polyunsaturated essential fatty acids, long-chain 
[omega-3] prevent development to more advanced stages of 
the disease), and 10) obesity (high correlation of the disease 
with high body mass index).20–24 
Although AMD is still considered a complex multifac-
torial disease with a heterogeneous phenotype, a genetic 
predisposition has been established in AMD patients. It is 
believed that the association of environmental factors and the 
involvement of different genes increase the predisposition 
for disease onset.25–30 Currently, several candidate genes are 
under investigation as inductors or protectors related with 
pathology.25,27,29,30 So AMD can be seen as the product of 
environmental factors and genetic predispositions.31 The 
study of gene polymorphisms may help to identify patients 
and families at high risk for the disease, and to establish an 
adequate response to treatment.25,30 These are emerging fields 
of great translational interest today.
AMD pathogenesis
The findings regarding molecular aspects of the biochemical 
and cellular pathophysiology of AMD suggest that the com-
plex formed by photoreceptors, RPE, Bruch’s membrane, and 
choriocapillaris creates a local predisposition to continuous 
oxidative stress, which is more pronounced in the macular 
region.32–34 Oxidative stress encourages the occurrence of an 
inflammatory process mediated in part by the complement 
activation, mainly at the level of the RPE/Bruch’s membrane 
junction. Patients with mutations in these proteins in the 
complement system components are less able to modulate 
the inflammatory response, resulting in constant, excessive 
cell damage with accumulation of extracellular waste, whose 
main histopathologic feature is the formation of drusen.34 
These changes involve the modification of the extracellular 
matrix and contribute to the maintenance of the inflammatory 
process by causing additional cellular damage. This chronic 
inflammatory response involves cellular components of the 
immune system and the classical and alternative pathways of 
the complement system (C2 and C3 complements, comple-
ment factor H and complement factor B).35–38 Progressive 
accumulation of abnormally metabolized extracellular mate-
rial, including cell membrane debris (the RPE’s phagocytic 
function), oxidized molecules (reactive oxygen products and 
oxidative stress), degraded extracellular matrix molecules, 
and the components of the complement system (activation 
of inflammatory mechanisms) is therefore a sign of the dam-
age caused by a chronic inflammatory process. The initial 
clinical manifestation of this inflammation is the appearance 
of drusen (accumulation of cellular waste material) and 
pigmentary changes (EPR degradation from accumulating 
lipofuscin), which over time, promotes the development of 
clinical manifestations of late stages of AMD in susceptible 
individuals (eg, atrophy and/or CNV). However, the role 
of choriocapillaris in the pathogenic cascade is not fully 
elucidated. Various treatments for AMD are currently under 
investigation, based on concepts related to this hypothesis 
of pathogenesis.
Thus, the evidence indicates that AMD is associated with 
oxidative damage, accumulation of lipofuscin inside RPE 
cells, chronic inflammation, and genetic mutations in certain 
proteins in the complement system. Various molecular targets 
have been identified that can serve as a basis for developing 
potential new treatments for the disease, including preventive 
treatments for early clinical forms and others for rescue, 
replacement, and regeneration in order to address compli-
cations in the late stages of geographic atrophy forms or 
structural alterations following CNV in the macular area.
Radiation and CNV
Several approaches have been effective in the treatment of 
CNV in the macular area, including laser treatment, photo-
dynamic therapy with veterporfin, and most recently, anti-
VEGF antibodies and fusion proteins, which have evolved 
considerably over the past two decades.39,40 Whereas treat-
ment modalities such as thermal laser photocoagulation and 
photodynamic therapy have been applied in selected cases 
of CNV in AMD and have yielded modest results in terms of 
improvement of vision, the introduction of drugs that directly 
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inhibit VEGF action has provided better visual prognosis. 
Combined therapies and association with intraocular steroids 
are also valid strategies.40
Radiation therapy has previously been studied as a 
treatment for solid vascularized intraocular tumors and wet 
AMD.41,42 Radiation is used to treat tumor cells and the for-
mation of new vessels for solid vascularized tumors in much 
the same way as in a proliferative wound healing process, 
because cells with high rates of proliferative activity are sen-
sitive to the effects of ionizing radiation.43,44 Histologically, 
the newly formed CNV complexes are composed of RPE 
and endothelial vascular cells, connective cells (fibroblasts), 
and local inflammatory cell populations (macrophages and 
plasmatic cells).45 Initially, the use of ionizing radiation for 
the AMD treatment was partially limited by the inevitable 
collateral damage to adjacent healthy ocular tissue deriving 
from the application of radiation through transscleral (sclera, 
choroid, and choriocapillaris) or transcorneal (cornea and 
lens) techniques to treat macular CNV.42 In the treatment 
of posterior choroidal melanoma by plaque brachytherapy, 
the total radiation doses that may lead to complication rates 
between 5% and 50% (at 5 years) are expressed by the tissue 
tolerance dose (TD) as TD5 and TD50, respectively. For the 
retina, TD5 and TD50 are 45 Gy and 65 Gy, respectively, 
suggesting that doses of 45 Gy–50 Gy can be safely tolerated 
by the foveal region.46,47 
More recently, approaches for delivering radiation 
therapy to retinal and subretinal tissues have been refined in 
the form of epimacular brachytherapy (EMBT; Vidion Neo-
vista, Inc., Newark, CA, USA) and stereotactic radiotherapy 
(teletherapy; IRay, Oraya Therapeutics, Inc., Newark, CA, 
USA), which deliver radiation focally or directionally to the 
neovascular lesion in the macula, while minimizing exposure 
of the neighboring healthy retina and other surrounding ocu-
lar tissues. The stereotactic radiotherapy uses a low-voltage 
X-ray system with a great advantage of not requiring invasive 
surgical procedures such as a pars plana vitrectomy, which 
is necessary in EMBT approach. 
The mechanism of action of radiotherapy in CNV in 
AMD is based on selective inhibition of the proliferation 
of endothelial cells of newly formed capillaries without 
affecting the cell activity related to the tissue repair 
mechanisms.48 Drugs which block VEGF, are effective in 
limiting the increased vascular permeability of CNV but 
they are not usually able to achieve CNV regression. CNV 
presents a different behavior from the normal surrounding 
native vasculature, characterized by uncontrolled growth and 
increased permeability. Radiation leads directly to capillary 
closure, which may be the reason for its efficacy in reducing 
bleeding.49 Histopathological findings suggest that endothe-
lial cell loss may occur up to a year after irradiation.50 The 
apoptotic effect of radiation is mainly the result of the direct 
action on the cellular DNA. Radiation significantly alters 
the nuclear DNA, leading to ruptures in the single or double 
strands and disturbing the purine base pairs. These changes 
affect cell division and directly modify the cell cycle.51 The 
radiation also interacts with other atoms or molecules inside 
the cell (particularly water) creating free radicals and reac-
tive oxygen products (ROS). These free elements induce 
additional indirect DNA damage.46 Other additional effects 
include the inhibition of cells responsible for the synthesis 
and secretion of pro-inflammatory growth factors and for 
modulating cell types related to scar tissue formation. The 
anti-inflammatory properties of radiation therapy may be 
desirable, since inflammatory events are the dominant 
factor in the progression of AMD and contribute to CNV 
development. A reduction in macrophage-mediated retinal 
inflammation has been demonstrated after irradiation.52 
The final property of radiation treatment is its anti-fibrotic 
effect.53 Radiation therapy may inhibit CNV metaplasia due 
to endothelial cell apoptosis that leads into fibrotic glia (disci-
form scar). Additionally, radiation may arrest the fibrovascu-
lar growth component induced in the angiogenic process.54,55 
Thus, radiation has anti-angiogenic, anti-inflammatory, and 
anti-fibrotic effects.
The biological effect of ionizing radiation is the prin-
ciple of ionization, in which the absorption of energy by 
an atom or molecule results in the ejection of one or more 
of its orbiting electrons, resulting in unstable and highly 
reactive compounds. Brachytherapy has been used with 
either palladium-103 (103Pd) or strontium (90Sr). Dosimetric 
studies have shown that localized application dispenses a 
much lower dose of radiation to the lens and the optic nerve, 
leading to external-beam therapy, thus significantly reducing 
adverse effects in these structures. Previous studies showed 
a dose on the target tissue of between 5 Gy and 24 Gy.55,56 
Beta radiation is composed of particles with a mass similar 
to that of electrons and gives a greater penetration power. 
However, beta radiation stops at a few meters of air or at a 
few centimeters of water, or biological tissue, meaning that it 
is very useful for surface radiation treatments in which deeper 
tissue penetration is undesirable. The penetration depends 
on the energy of the particles released in the decay process 
of a particular source. Strontium-90 has been found to be a 
clinically useful source of beta radiation because it emits 
only high-energy beta particles as it decays. Ruthenium-106 
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(106Ru) primarily emits beta radiation but also emits a small 
but significant degree of gamma irradiation.57 The half thick-
ness of 90Sr is 1.5 mm (this represents the radiation dose rate, 
which is attenuated by 50% after 1.5 mm penetration through 
water). The corresponding distance for 106Ru is 2.4 mm.43 
Therefore, among the emitters used in ophthalmology, 90Sr 
has the most marked attenuation in biological tissues, making 
it particularly suitable for ocular use.
Epimacular brachytherapy in AMD
Radiation therapy is currently under investigation again, in 
combination with anti-VEGF therapy for wet AMD (Table 1). 
Radiotherapy often produces a delayed response but retains 
one of its benefits – a much longer duration of action.51
EMBT, which was developed to deliver intraocular radia-
tion, places the source of radiation close to the CNV complex 
in the macular region. The beta radiation dose declines rap-
idly with increasing distance from the source, limiting radia-
tion exposure and mitigating the damage to adjacent normal 
tissue.51,58 The beta radiation used in EMBT is delivered via a 
pars plana vitrectomy with the removal of the vitreous body 
and the positioning of a probe over the CNV lesion. The end 
of the probe contains a source of 90Sr/Yttrium-90 radiation. 
The device is held in position for approximately 5 minutes, 
long enough to deliver 24 Gy to the CNV complex. A pre-
operative macular fluorescein angiogram is normally used to 
determine the area of greatest disease activity. Because beta 
radiation decreases with increasing distance from the origi-
nal source, the optic nerve receives approximately 2.4 Gy, 
and the lens only 0.56 mGy – far below the level of 2 Gy 
considered the threshold for cataract formation.51,59 Cataract 
formation after vitrectomy is also a common feature and has 
been described in 80% of eyes 2 years after the procedure.60 
Furthermore, vitrectomy itself may be helpful in treating 
AMD, since it limits vitreomacular adhesion.61 It has also 
been suggested that the removal of the vitreous gel increases 
the level of oxygen available to the inner layers of the retina 
via better diffusion from the aqueous humor.62,63 In addition, 
by increasing the oxygenation in the macular area, it may 
increase the formation of free radicals and therefore facilitate 
the degradation of cellular double-stranded DNA and prevent 
further CNV formation.51,64
In the initial feasibility study, 34 patients received 24 Gy 
for 5 minutes and were followed up for 3 years.65,66 Approxi-
mately 90% of eyes lost fewer than 15 letters from baseline, 
and 21% gained more than 15 letters. In these clinical trials, 
patients received an anti-VEGF injection at the time of 
surgery and again 1 month later.65 Thereafter, they received 
anti-VEGF therapy as PRN (pro re nata [as needed]) protocol, 
based on disease activity.66 Radiation treatment dramatically 
reduced the need for anti-VEGF therapy, with only eleven 
eyes requiring additional bevacizumab retreatment therapy 
over 3 years for a mean of three injections in all.66 The poten-
tial risks of intraocular radiation include retinopathy, optic 
neuropathy, and cataract. There were no severe radiation-
related adverse events, and 50% of phakic eyes experienced 
cataracts (Table 2).
These results were the basis for prospective, random-
ized controlled trials including treatment-naïve individuals 
(MERITAGE and CABERNET) and in individuals already 
treated with anti-VEGF therapy (MERLOT).40,58
The MERITAGE trial targeted patients with chronic active 
AMD who already required frequent injections of anti-VEGF 
therapeutics.67,68 Fifty-three eyes (53 patients) previously 
treated for wet AMD with repeated anti-VEGF therapy 
were also treated with single 24 Gy dose via EMBT (90Sr/
Yttrium-90 source) and were then followed up with monthly 
ocular coherence tomography. Participants were retreated with 
ranibizumab, administered monthly as PRN protocol. Before 
enrolment, the average rate of anti-VEGF injection was 0.45/
patient/month; during the 12-month follow-up period, the rate 
of retreatment was 0.29/patient/month.67 Recent results at 24 
months showed that 68.1% of participants lost fewer than 
15 letters, with a mean of 8.7 ranibizumab retreatments.68 
Common adverse events included conjunctival hemorrhage 
(71.7%) and cataract (30.2%). There was one case of non-
proliferative radiation retinopathy in the 24 months of follow-
up68 (Table 2). Overall, these results suggest that combination 
therapy with EMBT can stabilize wet AMD, thus decreasing 
the requirement for anti-VEGF therapy. However, the apparent 
reduction in ranibizumab retreatments was less evident over 
24 months than during the first year, and a moderate reduction 
in visual acuity persisted after 24 months of follow-up.
In the CABERNET trial, 494 treatment-naïve wet AMD 
patients were enrolled in a 2:1 randomization scheme to 
receive either 24 Gy of radiation with two monthly load-
ing injections of ranibizumab, followed by ranibizumab as 
needed.69 The control arm received three monthly loading 
injections of ranibizumab, followed by quarterly injections 
in a modified PIER protocol.54 Both arms also received 
monthly PRN retreatment. CABERNET was a prospective 
trial with a non-inferiority outcome. Over 24 months, EMBT 
did not meet the superiority endpoint for the proportion of 
participants gaining more than 15 letters (16% for the EMBT 
group versus 26% for the control group). This difference 
was statistically significant (in favor of controls) for occult 
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lesions, but not for predominantly classic and minimally 
classic lesions. The study also demonstrated that participants 
in the EMBT arm received less intravitreal therapy (IVT) 
(mean of 6.2 IVT) than those in the control arm (mean of 
10.4 IVT). However, at least one serious adverse event 
occurred in 54% of the EMBT arm (cataract) compared with 
18% in the control arm (Table 2). There was also one case 
of mild non-proliferative radiation retinopathy. The authors 
concluded that at 24 months of follow-up the data did not 
support the routine use of EMBT for treatment of naïve wet 
AMD, despite an acceptable safety profile.
The MERLOT trial is a non-commercial, multicenter, 
randomized controlled clinical study in patients who have 
already commenced anti-VEGF therapy (Table 1). The 
objective of the study is to evaluate the safety and efficacy 
of focal delivery of radiation for treating subfoveal CNV 
associated with established wet AMD previously treated 
with anti-VEGF therapy. It is hypothesized that EMBT will 
reduce the frequency of anti-VEGF retreatments required by 
patients, whilst maintaining visual acuity. The MERLOT trial 
will enroll participants at several UK NHS hospitals. In total, 
363 patients will be randomized in a 2:1 ratio, comparing 
epimacular brachytherapy and ranibizumab as required with 
ranibizumab monotherapy.40,58
Conclusion
The pathophysiology of wet AMD is complex and is not 
fully understood. Although anti-VEGF therapy has proven 
very successful, it is not effective for all patients, and the 
recommended therapy involves expensive monthly intra-
vitreal injections and clinical follow-up, with a high cost for 
public health services. The use of combination treatments 
will hopefully improve on the results of current anti-VEGF 
agent therapy and may result in improvements in vision and 
more convenient dosing regimens. Beta radiation therapy 
has a rapid decline in dose with increasing distance from 
the radiation source, limiting exposure and the damage to 
adjacent normal tissue. EMBT offers very precise dosing 
but requires a surgical procedure, which often leads to 
cataract formation in patients with phakic eyes at baseline. 
The vitrectomy itself may be beneficial in treating AMD 
by limiting vitreomacular adhesion, increasing the level of 
oxygen available to the inner layers of the retina, and facili-
tating the radiation mechanism action on the cells. However, 
at the present stage of research, the results of the clinical 
trials carried out to date are insufficient to justify extending 
routine use of EMBT for the treatment of wet AMD, despite 
an acceptable efficacy and safety profile.
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